Some Targeted and Immune Checkpoint Therapies for Non–Small Cell Lung Cancer
Target | Drug |
|---|---|
ALK rearrangement | AlectinibAlectinib BrigatinibBrigatinib EnsartinibEnsartinib LorlatinibLorlatinib |
BRAF mutation | Dabrafenib + trametinibDabrafenib + trametinib Encorafenib + binimetinibEncorafenib + binimetinib |
EGFR mutation | Amivantamab + lazertinibAmivantamab + lazertinib OsimertinibOsimertinib |
EGFR exon 20 | AmivantamabAmivantamab |
Inhibit blood vessel growth | BevacizumabBevacizumab Ramucirumab Ramucirumab |
Immune activation (checkpoint inhibitors) | AtezolizumabAtezolizumab CemiplimabCemiplimab DurvalumabDurvalumab IpilimumabIpilimumab NivolumabNivolumab PembrolizumabPembrolizumab |
ROS rearrangement | Crizotinib Crizotinib EntrectinibEntrectinib RepotrectinibRepotrectinib TaletrectinibTaletrectinib |
MET exon 14 skipping mutation | CapmatinibCapmatinib TepotinibTepotinib |
RET rearrangement | PralsetinibPralsetinib Selpercatinib Selpercatinib |
NTRK1, NRTK2, or NRTK3 gene fusion | EntrectinibEntrectinib LarotrectinibLarotrectinib RepotrectinibRepotrectinib |
NSCLC = Non–small cell lung cancer. | |